ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Stock Information for Carisma Therapeutics Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Carisma Therapeutics Inc Com

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April 
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
ProMIS Neurosciences Issues Letter to Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.